A5045076272- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer Immunotherapy and Biomarkers
- Cancer Genomics and Diagnostics
- Colorectal Cancer Treatments and Studies
- Pancreatic and Hepatic Oncology Research
- Advanced Breast Cancer Therapies
- RNA modifications and cancer
- Intraperitoneal and Appendiceal Malignancies
- HER2/EGFR in Cancer Research
- Gastric Cancer Management and Outcomes
- Lung Cancer Treatments and Mutations
- Gastrointestinal Tumor Research and Treatment
- Peptidase Inhibition and Analysis
- Neuroendocrine Tumor Research Advances
- Breast Cancer Treatment Studies
- Radiomics and Machine Learning in Medical Imaging
- Cancer Treatment and Pharmacology
- Immune cells in cancer
- Ferroptosis and cancer prognosis
- Genetic factors in colorectal cancer
- Folate and B Vitamins Research
- Lung Cancer Research Studies
- Health Systems, Economic Evaluations, Quality of Life
- RNA Research and Splicing
- Cancer, Lipids, and Metabolism
National University Cancer Institute, Singapore
2016-2025
National University of Singapore
2019-2025
National University Hospital
2020-2025
National University Health System
2015-2024
University of London
2022
London School of Hygiene & Tropical Medicine
2022
University Hospitals Seidman Cancer Center
2013
Case Western Reserve University
2013
Mayo Clinic in Arizona
2007-2011
Mayo Clinic
2007-2011
As the current therapeutic strategies for human hepatocellular carcinoma (HCC) have been proven to limited effectiveness, immunotherapy becomes a compelling way tackle disease. We aim provide humanised mouse (humice) models understanding of interaction between cancer and immune system, particularly human-specific drug testing.
Abstract Purpose: Transcription factor C/EBP-α (CCAAT/enhancer-binding protein alpha) acts as a master regulator of hepatic and myeloid functions multiple oncogenic processes. MTL-CEBPA is first-in-class small activating RNA oligonucleotide drug that upregulates C/EBP-α. Patients Methods: We conducted phase I, open-label, dose-escalation trial in adults with advanced hepatocellular carcinoma (HCC) cirrhosis, or resulting from nonalcoholic steatohepatitis liver metastases. received...
This randomized, multicenter, open-label, phase Ib/II study assessed durvalumab and tremelimumab in combination or as monotherapy for chemotherapy-refractory gastric cancer gastroesophageal junction (GEJ) cancer. Second-line patients were randomized 2:2:1 to receive plus (arm A), B) C), third-line received D). A tumor-based IFNγ gene signature was prospectively evaluated a potential predictive biomarker second- receiving the E). The coprimary endpoints objective response rate...
Abstract Purpose: To evaluate the mechanisms of how therapeutic upregulation transcription factor, CCAAT/enhancer-binding protein alpha (C/EBPα), prevents tumor progression in patients with advanced hepatocellular carcinoma (HCC) and different mouse models. Experimental Design: We conducted a phase I trial 36 HCC (NCT02716012) who received sorafenib as part their standard care, were given C/EBPα small activating RNA (saRNA; MTL-CEBPA) either neoadjuvant or adjuvant treatment. In preclinical...
Colorectal cancer (CRC) remains a significant global health challenge, ranking among the leading causes of cancer-related morbidity and mortality worldwide. Recent advancements in molecular characterization have revolutionized our understanding heterogeneity within colorectal tumors, particularly context tumor sidedness. Tumor sidedness, referring to location primary either right or left colon, has emerged as critical factor influencing prognosis treatment responses metastatic CRC. Molecular...
Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is a novel laparoscopic, delivery technique aiming to improve drug distribution and tissue penetration treat peritoneal metastases. Thus far, PIPAC oxaliplatin conducted at an arbitrary dose of 92 mg/m2. We phase I study establish safety tolerability.We used 3+3 dose-escalation design for patients with metastases from gastrointestinal tumors, after failure least first-line chemotherapy. Dose levels were planned 45, 60, 90, 120...
In a retrospective study of 126 adult patients with French-American-British-defined refractory anemia ringed sideroblasts (RARS), staging by the International Prognostic Scoring System was highly predictive survival outcome (P < 0.0001). addition, red blood cell (RBC) transfusion requirement at diagnosis = 0.001), but not number RBC units transfused during disease course 0.17), independently associated inferior survival. There were no correlations between and serum ferritin level, measured...
Abstract Background. Src, EphA2, and platelet-derived growth factor receptors α β are dysregulated in pancreatic ductal adenocarcinoma (PDAC). Dasatinib is an oral multitarget tyrosine kinase inhibitor that targets BCR-ABL, c-Src, c-KIT, receptor β, EphA2. We conducted a phase II, single-arm study of dasatinib as first-line therapy patients with metastatic PDAC. Methods. (100 mg twice day, later reduced to 70 day because toxicities) was orally administered continuously on 28-day cycle. The...
Recent development of multiple treatments for human hepatocellular carcinoma (HCC) has allowed the selection combination therapy to enhance effectiveness monotherapy. Optimal therapies is based on both HCC and its microenvironment. Therefore, it critical develop validate preclinical animal models testing clinical therapeutic solutions.We established cell line-based or patient-derived xenograft-based humanized-immune-system mouse with subcutaneous orthotopic HCC. Mice were injected...
Hepatocellular carcinoma (HCC) remains difficult to treat due limited effective treatment options. While the proteasome inhibitor bortezomib has shown promising preclinical activity in HCC, clinical trials of showed no advantage over standard-of-care sorafenib, highlighting need for more clinically relevant therapeutic strategies. Here, we propose that rational drug combination design and validation patient-derived HCC avatar models such as xenografts (PDXs) organoids can improve...
NTRK fusions result in constitutively active oncogenic TRK proteins responsible for ∼ 0.2 % of non-small cell lung cancer (NSCLC) cases. Approximately 40 patients with advanced NSCLC develop CNS metastases; therefore, treatments intracranial (IC) efficacy are needed. In an integrated analysis three phase I/II studies (ALKA-372-001: EudraCT 2012-000148-88; STARTRK-1: NCT02097810; STARTRK-2: NCT02568267), entrectinib, a potent, CNS-active, inhibitor, demonstrated fusion-positive (fp)...
We evaluated the relevance of PD-1+CD8+ T-cells in gastric cancer (GC) including prognostic significance, association with chemotherapy and immunotherapy sensitivity correlations tumor microenvironment (TME).Discovery cohort: GC samples were for AE1/3, CD8, PD-1, Ki-67 Granzyme-B expression fluorescence-based multiplex immunohistochemistry (mIHC). Validation cohorts: we analyzed bulk RNAseq datasets from TCGA, "3G" trial an phase 2 trial. The cox proportional hazards model was used to...
560 Background: The majority of pts with mCRC have microsatellite stable (MSS) tumors minimal response to PD-L1/PD-1 blockade. MEK inhibition upregulates tumor major histocompatibility complex-I expression, promotes intratumoral T-cell accumulation and improves anti–PD-L1 responses (Ebert, Immunity. 2016), supporting clinical evaluation combined (A) plus MEKi (C) in mCRC. Methods: Pts chemotherapy-refractory or locally advanced were evaluated. A was administered IV q2w at 800 mg. C dosed PO...
Tumor-specific antibody drugs can serve as cancer therapy with minimal side effects. A humanized antibody, PRL3-zumab, specifically binds to an intracellular oncogenic phosphatase PRL3, which is frequently expressed in several cancers. Here we show that PRL3-zumab inhibits PRL3+ cells vivo, but not vitro. PRL3 antigens are detected on the cell surface and outer exosomal membranes, implying 'inside-out' externalization of PRL3. a manner consistent classical antibody-dependent cell-mediated...
1574 Background: Most treatment guidelines recommend chemotherapy at maximum tolerated doses, which does not always lead to optimal efficacy, but implicitly results in toxicity. To overcome this challenge, we developed CURATE.AI, a small data, AI-derived platform that harnesses only patient’s own prospectively/longitudinally acquired data dynamically identify their and personalized doses. We subsequently harnessed CURATE.AI modulate individualized doses for patients prospective clinical...